Heme synthesis disorders: Pathology review

Last updated: November 01, 2022

Heme synthesis disorders: Pathology review

Modulo 3 BPT

Modulo 3 BPT

Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Gene regulation
Epigenetics
Amino acids and protein folding
Protein structure and synthesis
Nucleotide metabolism
DNA replication
Lac operon
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Lesch-Nyhan syndrome
Orotic aciduria
Adenosine deaminase deficiency
Xeroderma pigmentosum
Li-Fraumeni syndrome
Bloom syndrome
Fanconi anemia
McCune-Albright syndrome
Acute radiation syndrome
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Inheritance patterns
Independent assortment of genes and linkage
Evolution and natural selection
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Hereditary spherocytosis
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Krabbe disease
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Primary ciliary dyskinesia
Phenylketonuria (NORD)
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Muscular dystrophy
Ornithine transcarbamylase deficiency
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Iron deficiency anemia
Sideroblastic anemia
Anemia of chronic disease
Lead poisoning
Hemolytic disease of the newborn
Autoimmune hemolytic anemia
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Aplastic anemia
Megaloblastic anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Diamond-Blackfan anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Vitamin K deficiency
Bernard-Soulier syndrome
Glanzmann's thrombasthenia
Hemolytic-uremic syndrome
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antiphospholipid syndrome
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Langerhans cell histiocytosis
Mastocytosis (NORD)
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Prostate cancer
Benign prostatic hyperplasia
Testicular cancer
Ovarian surface epithelial tumors
Ovarian germ cell tumors
Ovarian sex-cord stromal tumors
Endometrial cancer
Cervical cancer
Breast cancer
Disorders of sex chromosomes: Pathology review
Testicular tumors: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Breast cancer: Pathology review
Colorectal cancer
Carcinoid syndrome
Irritable bowel syndrome
Colorectal polyps and cancer: Pathology review
Seizures and epilepsy
Dementia: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Neuromuscular junction disorders: Pathology review
Adult brain tumors: Pathology review
Inflammatory bowel disease: Pathology review
Bowel obstruction

Transcript

Watch video only

18 year old Christopher is brought to the emergency room by his best friend Paul after suddenly getting abdominal cramps at a party. Cristopher goes to the restroom while you ask Paul a few questions. Paul tells you that Cristopher was behaving strangely at the party, and adds that it was his first time drinking alcohol. When Christopher comes back from the restroom, he tells you that his urine had a reddish color. Unfortunately, his family history is unknown, since he was adopted at a very young age. Next to him, there’s 45 year old Magdalene, who developed skin blisters on her hands and forearms after spending the day having some alcoholic cocktails on the beach. Upon further questioning, Magdalene mentions that her urine had a strange tea color earlier. You decide to take a look at her past medical history, which reveals that Magdalene had hepatitis C a few weeks ago.

Based on the initial presentation, both Christopher and Magdalene seem to have some form of heme synthesis disorder. Heme synthesis disorders are associated with hereditary or acquired deficiencies of enzymes that are involved in the heme synthesis pathway. But first let’s go over the heme synthesis pathway really quick! It’s important to remember that heme synthesis occurs in the liver, where heme is used in the cytochrome P450 enzyme system, as well as in the bone marrow where heme is used to synthesize hemoglobin. Now, heme synthesis begins in the mitochondria, where succinyl CoA binds to glycine via aminolevulinic acid or ALA synthase to produce aminolevulinic acid or ALA. Remember, this is the rate-limiting step for heme synthesis, meaning that it’s the slowest step in the pathway, and it requires vitamin B6, or pyridoxine, as a cofactor. What’s also high yield is that this step is stimulated by low levels of heme, while it’s inhibited by elevated levels of heme, as well as glucose and hemin, which is an oxidized form of heme that contains ferric iron or Fe3+ with chloride. Okay, then, ALA is transported to the cytosol, where it gets converted to porphobilinogen or PBG via aminolevulinic acid or ALA dehydratase, which is a zinc-containing enzyme. From there, four molecules of porphobilinogen come together to form hydroxymethylbilane with the help of porphobilinogen deaminase. Note that porphobilinogen deaminase is sometimes called uroporphyrinogen I synthase or hydroxymethylbilane synthase, or HMBS for short. Afterwards, hydroxymethylbilane is converted via uroporphyrinogen III cosynthase to uroporphyrinogen III, which is then turned to coproporphyrinogen III via uroporphyrinogen decarboxylase Next, coproporphyrinogen III is brought back into the mitochondria and converted into protoporphyrinogen IX, which is then converted to protoporphyrin IX. Lastly, the enzyme ferrochelatase adds an iron molecule to protoporphyrin IX, and we’ve got ourselves a complete molecule of heme!

Alright, now, for your exams, the most high yield causes of heme synthesis disorders are sideroblastic anemia, lead poisoning, acute intermittent porphyria, and porphyria cutanea tarda.

Starting with sideroblastic anemia, which can be genetic or acquired. The most common genetic cause is an X-linked mutation in the gene coding for ALA synthase. On the other hand, the most important acquired cause is vitamin B6 or pyridoxine deficiency. For your exams, remember that this can result from inadequate dietary intake, chronic alcohol abuse, and treatment with isoniazid. In any case, heme synthesis is impaired, so there’s an excess of iron that’s not being used and ends up accumulating throughout the body, particularly in the heart, liver, spleen, kidneys, and the intestines. As a result, individuals with sideroblastic anemia may develop cardiomyopathy, cirrhosis, enlarged spleen, kidney failure, and diarrhea.

Diagnosis of sideroblastic anemia relies on blood tests showing microcytic and hypochromic red blood cells, meaning that they are smaller and paler than normal, which indicates that they contain low quantities of hemoglobin. In addition, blood tests will reveal high iron and high ferritin, which stores iron, as well as a high saturation of transferrin, which is a molecule that transports iron in the blood, and normal or low total iron binding capacity or TIBC, which indicates the amount of unbound transferrin in the blood. In a peripheral blood smear, what we expect to see is red blood cells with basophilic stippling, which refers to tiny blue or purple granules of ribosomal RNA that are dispersed throughout the cytoplasm. And that’s a high yield fact! Additionally, pappenheimer bodies or cytoplasmic granules of iron may also be observed inside the red blood cells. Finally, upon a bone marrow biopsy, a Prussian blue stain can show the iron-laden mitochondria forming a ring around the nucleus, producing the classic ringed sideroblast appearance.

All right, now treatment of sideroblastic anemia involves managing iron overload with therapeutic phlebotomy or bloodletting, as well as deferoxamine, an iron chelating agent. In addition, pyridoxine supplementation can also be useful. Finally, severe cases may require a bone marrow or liver transplant.

Now, another cause of acquired sideroblastic anemia is lead poisoning. However, what’s important for you to know is that lead inhibits both ALA dehydratase and ferrochelatase. As a result, there’s build up of ALA and protoporphyrin IX in the blood. Now, remember that lead poisoning usually occurs in children ingesting lead-containing paint chips, as well as adults who inhale lead while working in mines, or those who are frequently in contact with batteries or bullets. High yield symptoms of lead poisoning include abdominal pain, headaches, memory loss, and constipation. Lead can also accumulate and form lead lines on the metaphysis of long bones. Other telltale signs include Burton lines, which are blue lead lines that can appear at the gingiva. Finally, some individuals may present with wrist and foot drop due to demyelination of peripheral nerves causing peripheral neuropathy,

Now, for diagnosis of lead poisoning, blood tests would obviously show high lead levels, in addition to the sideroblastic anemia. Finally, X-rays might also be done to look for lead lines on long bones.

The main treatment for lead poisoning consists of chelating agents like succimer for children and dimercaprol or EDTA for adults.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Hemoglobin: Emerging marker in stable coronary artery disease" Chronicles of Young Scientists (2011)